Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
about
Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studiesIncretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitorsSafety of dipeptidyl peptidase 4 inhibitors: a perspective reviewUpdate on the treatment of type 2 diabetes mellitusAssociation Between Severe Hypoglycemia and Cardiovascular Disease Risk in Japanese Patients With Type 2 DiabetesA systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapyEmerging gliptins for type 2 diabetes.Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-up.Incretin-based therapies in prediabetes: Current evidence and future perspectivesEfficacy and safety of sitagliptin added to insulin in Japanese patients with type 2 diabetes: the EDIT randomized trial.Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials.Short-term and long-term effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with renal impairment: a meta-analysis of randomized controlled trials.Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study.Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agentProfile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability.Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.The dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetes mellitus in challenging patient groups.Effectiveness and Safety of Sitagliptin in Patients with Beta-thalassaemia Major and Diabetes Mellitus: A Case Series.Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.Cardiovascular effects of gliptins.Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013.Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety.Alogliptin benzoate for the treatment of type 2 diabetes.The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.Linagliptin: an update of its use in patients with type 2 diabetes mellitus.Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.Managing comorbidities in patients with chronic heart failure: first, do no harm.Dipeptidyl peptidase-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes.The efficacy of vildagliptin in korean patients with type 2 diabetesEffects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers.Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas.Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes.Cardiovascular safety of therapies for type 2 diabetes.Uncertainties around incretin-based therapies: A literature review.DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials.Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies.Incretin - based therapy in diabetes mellitus: present scenario and expanding horizonsSafety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies.Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min).
P2860
Q24288949-EB7E3EED-63BB-4C53-9956-65A5E1653DD3Q26778608-D1ED4BC1-5054-4C23-BA0E-F78B139A8F99Q26863262-72874C49-F5C6-4620-A321-38026F06DEA2Q28073342-4739C211-3A5F-4337-8929-EA1D381A1276Q28073762-F1B20B8B-51B2-455C-9EF1-4A6BC03E7738Q33859245-DBFB43AB-71B2-4B46-BE49-67E9404AA054Q34347884-CC25E132-704D-46AC-973C-7CB525E5098AQ34586376-EF09568E-4E71-4E35-8231-22A95DACF03CQ34699191-EB9FEC5D-6070-4551-B5AA-8A216779B9A0Q35225372-893B25AB-8A8D-4C28-8C1C-AE35703E02DDQ35236019-7643F922-24B3-4188-AAFC-B72ED5C84D0FQ35798155-10C38385-92E7-495E-BCFB-1B56DC53BB0CQ35808043-10D31EE5-59F7-4CED-9A94-4C0B8F6420EFQ36192977-A96C3879-58F4-4340-BBE3-40009FF62BEEQ36960161-DAC8E955-9348-469E-A67B-96D1BD014B44Q37195882-0AB28296-5AEC-4A7A-BA4E-4478C22980ABQ37502682-850BED90-79AD-4CA1-978A-6D2BBC0D957BQ37577871-AE8571F5-FB14-41F5-9D38-2323B0DBC51FQ37737474-0544080C-130E-4AE1-AD0E-AEA787E215A5Q38072259-B6EC5CF0-D86D-4658-A263-144D024C12AEQ38089327-3CD40E85-CA2E-4F7B-96FB-94669AFCABB5Q38126945-15D697E3-9908-400E-B417-729A47A2D6CFQ38197275-9CF9A772-3A62-416D-BD72-6D0EFBAC912BQ38211881-F0BEF498-FD93-4DD6-B7F4-47A083C4F41CQ38236774-8A65FA6C-4F23-421A-82DF-B0E6D9548DB4Q38258278-8C139D99-AF5A-4DC2-BCA7-E56F003DF962Q38335751-17DFB199-A62F-4A69-BE7F-A418A9E22A65Q38402807-595E63D2-84A4-4B3B-9372-AACECF2A9D25Q38416814-D3AA2C81-D5B6-4ECA-BB9F-A0C27E358B9FQ38452916-A960CD31-B02B-4F78-9EFB-C13CFC4142BAQ38625769-DBEE5C00-E70E-4EB4-9823-38D32F826460Q38644587-CDA7D7E4-48C6-4753-9936-8054B11AD941Q38828606-E4424575-1EBD-4D1F-9317-01924D2A661FQ38960547-C898AEC9-C01E-42F4-8FBF-5029BCFE702AQ39145953-4DC77CBD-79EF-4EE8-955F-32F5D2485CF1Q40487459-A367D348-201A-4FE5-A56F-6C6513046CB8Q41966262-41C0615D-CD72-493A-8C9A-46CAD8A37D82Q42381260-F885A251-D2EC-496E-BD79-A299BF1ABB20Q44548336-25086F4D-08CE-4380-A774-9C0287DD4F1DQ53519441-C966637B-9B8D-4B2A-B67E-136456DE249F
P2860
Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Longer term safety of dipeptid ...... atic review and meta-analysis.
@en
type
label
Longer term safety of dipeptid ...... atic review and meta-analysis.
@en
prefLabel
Longer term safety of dipeptid ...... atic review and meta-analysis.
@en
P2860
P1476
Longer term safety of dipeptid ...... atic review and meta-analysis.
@en
P2093
P2860
P304
P356
10.1111/J.1463-1326.2012.01610.X
P577
2012-05-17T00:00:00Z